| Cancer Research | Lifetime | 59 | DE 3 | 99.71 |
| Oncology | Lifetime | 118 | DE 4 | 99.80 |
| Reproductive Medicine | Lifetime | 673 | DE 14 | 93.51 |
| Oncology | 2021-2025 | 42 | DE 4 | 99.77 |
| Cancer Research | 2021-2025 | 20 | DE 1 | 99.32 |
| Pulmonary and Respiratory Medicine | 2021-2025 | 435 | DE 19 | 95.38 |
| Cancer Cells and Metastasis | Lifetime | 41 | DE 3 | 99.66 |
| Cancer Immunotherapy and Biomarkers | Lifetime | 71 | DE 2 | 99.80 |
| Breast Cancer Treatment Studies | Lifetime | 51 | DE 6 | 99.80 |
| Cancer Genomics and Diagnostics | Lifetime | 108 | DE 5 | 99.73 |
| HER2/EGFR in Cancer Research | Lifetime | 43 | DE 5 | 99.73 |
| Cancer, Hypoxia, and Metabolism | Lifetime | 315 | DE 25 | 99.05 |
| Cancer Treatment and Pharmacology | Lifetime | 280 | DE 13 | 99.15 |
| Advanced Breast Cancer Therapies | Lifetime | 102 | DE 9 | 99.06 |
| Cancer, Lipids, and Metabolism | Lifetime | 307 | DE 12 | 98.76 |
| Ovarian cancer diagnosis and treatment | Lifetime | 443 | DE 15 | 98.17 |
| Breast Lesions and Carcinomas | Lifetime | 242 | DE 10 | 98.12 |
| Inflammatory mediators and NSAID effects | Lifetime | 399 | DE 13 | 97.60 |
| Molecular Biology Techniques and Applications | Lifetime | 432 | DE 39 | 96.86 |
| Metabolomics and Mass Spectrometry Studies | Lifetime | 827 | DE 77 | 96.55 |
| Cancer, Stress, Anesthesia, and Immune Response | Lifetime | 291 | DE 16 | 94.10 |
| PARP inhibition in cancer therapy | Lifetime | 437 | DE 29 | 95.13 |
| PI3K/AKT/mTOR signaling in cancer | Lifetime | 637 | DE 16 | 95.47 |
| Cancer Mechanisms and Therapy | Lifetime | 870 | DE 50 | 92.45 |
| Breast Cancer Treatment Studies | 2021-2025 | 19 | DE 5 | 99.75 |
| Cancer Genomics and Diagnostics | 2021-2025 | 93 | DE 5 | 99.23 |
| HER2/EGFR in Cancer Research | 2021-2025 | 24 | DE 4 | 99.47 |
| Cancer Cells and Metastasis | 2021-2025 | 47 | DE 4 | 97.61 |
| Cancer Treatment and Pharmacology | 2021-2025 | 56 | DE 8 | 98.82 |
| Cancer Immunotherapy and Biomarkers | 2021-2025 | 289 | DE 9 | 98.90 |
| Advanced Breast Cancer Therapies | 2021-2025 | 163 | DE 10 | 97.16 |
| PARP inhibition in cancer therapy | 2021-2025 | 159 | DE 7 | 94.57 |
| BRCA gene mutations in cancer | 2021-2025 | 422 | DE 12 | 89.81 |
| DNA Repair Mechanisms | 2021-2025 | 680 | DE 31 | 82.36 |
| Cancer-related Molecular Pathways | 2021-2025 | 815 | DE 31 | 74.10 |
| Breast Lesions and Carcinomas | 2021-2025 | 768 | DE 49 | 76.09 |
| TGF-β signaling in diseases | 2021-2025 | 565 | DE 31 | 29.33 |
| Caveolin-1 and cellular processes | 2021-2025 | 544 | DE 34 | 16.75 |
